Regulatory affairs is the function within the pharmaceutical industry responsible for ensuring that drugs, biologics, and medical devices comply with the rules set by government agencies before, during, and after they reach patients. It spans every stage of a product’s life, from early development through clinical trials, market approval, and ongoing safety monitoring. If a pharmaceutical company wants to sell a product legally, regulatory affairs professionals are the ones who make that possible.
What Regulatory Affairs Professionals Actually Do
At its core, regulatory affairs is about translating science into the structured formats that regulatory agencies require. When a company develops a new drug, regulatory affairs teams guide the process of assembling and submitting the evidence that proves the product is safe, effective, and manufactured to consistent quality standards. This involves coordinating with scientists, clinicians, manufacturing teams, and legal departments to compile thousands of pages of data into formal applications.
The work shifts depending on where a product sits in its lifecycle. Early on, regulatory affairs professionals help design development strategies that align with agency expectations, so the company doesn’t spend years generating data that won’t satisfy reviewers. During clinical trials, they prepare the applications that allow testing in humans. When a drug is ready for market, they assemble the full submission package and manage the back-and-forth with agency reviewers. After approval, they handle label updates, safety reporting, and compliance with manufacturing standards.
Regulatory affairs also covers medical devices, diagnostics, gene therapies, vaccines, and combination products that blend a drug with a device (like a prefilled syringe). Each product type follows its own regulatory pathway, and professionals in this field need to know which rules apply and how they overlap.
Key Regulatory Agencies Around the World
The most prominent regulatory body is the U.S. Food and Drug Administration (FDA), which oversees drugs, biologics, and devices sold in the United States. In Europe, the European Medicines Agency (EMA) coordinates with a network of 30 national regulatory authorities across the EU and associated countries. Other major agencies include Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada.
Each agency has its own requirements, timelines, and review standards. A drug approved in the U.S. isn’t automatically approved in Europe or Japan. Regulatory affairs teams at global companies often manage parallel submissions to multiple agencies, adapting the same core data to meet each one’s specific formatting and evidentiary requirements. The World Health Organization also maintains a list of agencies it recognizes as meeting international standards, which helps streamline approvals in countries that rely on WHO assessments.
The Drug Approval Process in the U.S.
In the United States, a new drug moves through a series of formal submissions to the FDA. The first major filing is an Investigational New Drug application (IND). Federal law prohibits shipping unapproved drugs across state lines, so a company must file an IND to get an exemption that allows it to distribute the drug to clinical trial sites. The IND includes preclinical data from lab and animal studies, along with the proposed plan for human testing.
Once clinical trials produce sufficient evidence of safety and effectiveness, the company submits a New Drug Application (NDA). This is the comprehensive package that includes chemistry data, pharmacology results, clinical trial outcomes, statistical analyses, and proposed labeling. If the FDA approves the NDA, the drug can be marketed in the U.S.
Generic drugs follow a shorter path called an Abbreviated New Drug Application (ANDA). Generic applicants don’t need to repeat the clinical trials that proved safety and effectiveness for the original drug. Instead, they demonstrate that their product is bioequivalent, meaning it performs the same way in the body as the brand-name version. This streamlined process is what makes generic drugs less expensive to bring to market. For biological products like vaccines and cell therapies, a separate application called a Biologics License Application (BLA) is used.
How Submissions Are Structured
Regulatory submissions follow a standardized format called the electronic Common Technical Document (eCTD), which is accepted by agencies worldwide. It organizes all the required information into five modules. Module 1 contains administrative information and is the only section that varies by country. Module 2 provides overviews and summaries of the data. Module 3 covers manufacturing quality, including how the drug is made and tested for consistency. Module 4 contains the full nonclinical study reports from lab and animal testing. Module 5 holds the clinical study reports from human trials.
Building an eCTD submission is one of the most technically demanding tasks in regulatory affairs. A single NDA can run to hundreds of thousands of pages, and every section must be internally consistent, properly cross-referenced, and formatted to precise technical specifications. Errors or gaps can delay review by months.
Good Clinical Practice and Compliance Standards
Clinical trials must follow an international standard called Good Clinical Practice (GCP), developed by the International Council for Harmonisation (ICH). GCP is both an ethical and scientific framework. Its core principles require that trials protect the rights, safety, and well-being of participants, that trial designs generate reliable results, and that an independent ethics board reviews each study before it begins and periodically throughout its conduct.
GCP also requires that roles and responsibilities in a trial are clearly documented. Sponsors can delegate tasks to other organizations, but they retain overall responsibility for compliance. All essential records must be retained securely and made available to regulatory authorities, auditors, and ethics boards on request. Quality isn’t treated as a final checkpoint but is expected to be built into the design and conduct of the trial from the start, with strategies in place to detect and prevent serious noncompliance.
Regulatory affairs professionals are responsible for ensuring that a company’s clinical programs meet these standards. A trial that violates GCP can have its data rejected by regulators, potentially derailing years of development work.
What Happens After Approval
A drug’s regulatory obligations don’t end when it reaches the market. The FDA maintains postmarketing surveillance programs specifically because not all safety issues are visible during clinical trials, which typically involve thousands of patients over a limited time period. Once millions of people start using a drug, rarer side effects can emerge.
Manufacturers are required by regulation to submit adverse event reports to the FDA. The agency collects these in a database called the FDA Adverse Event Reporting System (FAERS), which supports ongoing safety surveillance for all approved drugs and biological products. Manufacturers must also report manufacturing errors, accidents, and deviations from quality standards.
Based on this postmarket data, the FDA can take several actions: updating a product’s labeling with new safety information, issuing safety communications to healthcare professionals, or in rare cases reevaluating whether the drug should remain on the market at all. Regulatory affairs teams manage each of these interactions, preparing the required reports and coordinating any labeling changes with the agency.
AI in Regulatory Submissions
Artificial intelligence is beginning to reshape how regulatory work gets done. In early 2024, the FDA established a Quantitative Medicine Center of Excellence to coordinate the use of AI and other quantitative tools in drug evaluation. By May 2025, the agency completed its first AI-assisted scientific review pilot and announced plans for an agency-wide rollout. On the industry side, companies are exploring AI for tasks like literature review, data summarization, and dossier preparation.
Europe is taking a parallel but distinct approach. The EU’s AI Act, adopted in 2024, introduced a risk-based framework that classifies medical AI systems as high-risk and imposes requirements around transparency, human oversight, and bias mitigation. Regulatory affairs professionals increasingly need to understand both the opportunities AI offers for streamlining submissions and the compliance obligations that come with using it.
Education and Career Path
Most regulatory affairs professionals hold at least a bachelor’s degree in a life science or clinical science field, and many have graduate degrees. Some universities now offer dedicated certificates, master’s programs, and doctoral programs in regulatory affairs. The Regulatory Affairs Certification (RAC), offered by the Regulatory Affairs Professionals Society, is a widely recognized credential. It isn’t required to work in the field, but it can be especially valuable for professionals at early and mid-career stages looking to demonstrate specialized expertise.
Entry-level roles often involve document management, submission formatting, or supporting senior staff with regulatory filings. With experience, professionals move into strategy roles where they advise on development plans, lead agency interactions, and make decisions about which markets to pursue and when. Senior regulatory leaders sit at the intersection of science, business, and policy, shaping how a company brings its products to patients across the world.